You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Medtronic
Baxter
Express Scripts
Merck

Last Updated: July 3, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021527


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

NDA 021527 describes ATROVENT HFA, which is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from two suppliers. There are three patents protecting this drug. Additional details are available on the ATROVENT HFA profile page.

The generic ingredient in ATROVENT HFA is ipratropium bromide. There are eight drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the ipratropium bromide profile page.
Summary for 021527
Tradename:ATROVENT HFA
Applicant:Boehringer Ingelheim
Ingredient:ipratropium bromide
Patents:3
Formulation / Manufacturing:see details
Pharmacology for NDA: 021527
Mechanism of ActionCholinergic Antagonists
Medical Subject Heading (MeSH) Categories for 021527
Suppliers and Packaging for NDA: 021527
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ATROVENT HFA ipratropium bromide AEROSOL, METERED;INHALATION 021527 NDA Boehringer Ingelheim Pharmaceuticals Inc. 0597-0087 0597-0087-17 1 CANISTER in 1 CARTON (0597-0087-17) > 200 AEROSOL, METERED in 1 CANISTER
ATROVENT HFA ipratropium bromide AEROSOL, METERED;INHALATION 021527 NDA A-S Medication Solutions 50090-0961 50090-0961-0 1 CANISTER in 1 CARTON (50090-0961-0) > 200 AEROSOL, METERED in 1 CANISTER

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:AEROSOL, METERED;INHALATIONStrength0.021MG/INH
Approval Date:Nov 27, 2004TE:RLD:Yes
Patent:  Start TrialPatent Expiration:May 26, 2020Product Flag?YSubstance Flag?Delist Request?
Patent:  Start TrialPatent Expiration:May 26, 2020Product Flag?YSubstance Flag?Delist Request?
Patent:  Start TrialPatent Expiration:Jan 17, 2030Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 021527

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim ATROVENT HFA ipratropium bromide AEROSOL, METERED;INHALATION 021527-001 Nov 27, 2004   Start Trial   Start Trial
Boehringer Ingelheim ATROVENT HFA ipratropium bromide AEROSOL, METERED;INHALATION 021527-001 Nov 27, 2004   Start Trial   Start Trial
Boehringer Ingelheim ATROVENT HFA ipratropium bromide AEROSOL, METERED;INHALATION 021527-001 Nov 27, 2004   Start Trial   Start Trial
Boehringer Ingelheim ATROVENT HFA ipratropium bromide AEROSOL, METERED;INHALATION 021527-001 Nov 27, 2004   Start Trial   Start Trial
Boehringer Ingelheim ATROVENT HFA ipratropium bromide AEROSOL, METERED;INHALATION 021527-001 Nov 27, 2004   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
McKesson
AstraZeneca
Medtronic
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.